Lv5
810 积分 2023-03-21 加入
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting
2个月前
已完结
IL-27 elicits a cytotoxic CD8+ T cell program to enforce tumour control
3个月前
已完结
Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
6个月前
已完结
Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells
8个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
8个月前
已完结
Anti-CD19/CD8 bispecific T cell engager for the potential treatment of B cell malignancies
10个月前
已完结
Harnessing CD8 T cell responses using PD-1–IL-2 combination therapy
1年前
已完结
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm andimmune-mediated control of epithelial cancers
1年前
已完结
Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
1年前
已完结
FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy
1年前
已完结
皖公网安备34019202002308
